Clinical Trials
105 trials68Ga-DOTATATE Neuroblastoma Imaging Pilot
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
BEACON
University of Birmingham
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
PEDS-PLAN
Milton S. Hershey Medical Center
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
Methionine PET/CT Studies In Patients With Cancer
St. Jude Children's Research Hospital
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
Shaare Zedek Medical Center
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
ANTARES
Instituto do Cancer do Estado de São Paulo
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
New Approaches to Neuroblastoma Therapy Consortium
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AflacST1502
Emory University
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Milton S. Hershey Medical Center
NMTT
Milton S. Hershey Medical Center
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
Tianjin Medical University Cancer Institute and Hospital
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
New Approaches to Neuroblastoma Therapy Consortium
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
Masonic Cancer Center, University of Minnesota
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
NEUROBLASTOTEP
Institut Curie
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Nationwide Children's Hospital
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
M.D. Anderson Cancer Center
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
MIBG
Nationwide Children's Hospital
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
STIR
Medical College of Wisconsin
LuDO-N
Karolinska University Hospital
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
NICE
Fundació Sant Joan de Déu
Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
University of California, San Francisco
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Milton S. Hershey Medical Center
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
Milton S. Hershey Medical Center
METRO-NB2012
University of Cologne
UVA-Gen001
University of Virginia
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
University of Iowa
NB2013-HR
University of Cologne
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
N2011-01
New Approaches to Neuroblastoma Therapy Consortium
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma
University Medicine Greifswald
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
University of Pittsburgh
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
University of Iowa